Model List of Essential Medicines

☐

Abacavir General information

Section
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
- Oral > Solid: 300 mg tablet (as sulfate)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Abacavir + dolutegravir + lamivudine General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Abacavir + lamivudine General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Abacavir + lamivudine + lopinavir + ritonavir General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Aciclovir General information

Section
Antiherpes medicines
- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Indications

Herpes simplex infections Zoster Varicella

☐

Atazanavir General information

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

☐

Atazanavir + ritonavir General information

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

☐

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate General information

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

☐

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide General information

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

☐

Daclatasvir General information

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

Chronic hepatitis C

☐

Daclatasvir + sofosbuvir General information

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

Chronic hepatitis C

☐

Darunavir General information

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Dasabuvir General information

Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
- Oral > Solid: 250 mg tablet

Indications
Chronic hepatitis C
☐

Didanosine General information

Section
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Dolutegravir General information

Section
Antiretrovirals > Integrase inhibitors
- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Dolutegravir + lamivudine + tenofovir General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Efavirenz General information

Section
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
- Oral > Solid: 600 mg tablet

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Efavirenz + emtricitabine + tenofovir General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Efavirenz + lamivudine + tenofovir General information

Section

Fixed-dose combinations of antiretrovirals
- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Elbasvir + grazoprevir General information

Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
- Oral > Solid: 50 mg + 100 mg

Indications
Chronic hepatitis C
☐

Emtricitabine General information

Section
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Emtricitabine + rilpivirine + tenofovir alafenamide General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 200 mg + 25 mg + 25 mg

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Emtricitabine + tenofovir General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
☐

Emtricitabine + tenofovir alafenamide General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Entecavir General information

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg

Indications
Chronic hepatitis B
☐

Glecaprevir + pibrentasvir General information

Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications
Chronic hepatitis C
☐

Indinavir General information

Section
Antiretrovirals > Protease inhibitors
- Oral > Solid: 400 mg (as sulfate)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information

Section
Medicines for prevention of HIV-related opportunistic infections
- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications
Other specified prophylactic measures
☐

Lamivudine General information

Section
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Lamivudine + nevirapine + zidovudine General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Lamivudine + tenofovir General information

Section
Fixed-dose combinations of antiretrovirals
Indications
Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus
☐

Lamivudine + zidovudine General information

Section
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Ledipasvir + sofosbuvir General information

Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
- Oral > Solid: 90 mg + 400 mg tablet

Indications
Chronic hepatitis C
☐

Lopinavir + ritonavir General information

Section
Antiretrovirals > Protease inhibitors
- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Nelfinavir General information

Section
Antiretrovirals > Protease inhibitors
- Oral > Solid: 250 mg (as mesilate)
- Oral > Other: 50 mg per g oral powder

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Nevirapine General information

Section
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Ombitasvir + paritaprevir + ritonavir General information

Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications
Chronic hepatitis C
☐

Oseltamivir General information

Section
Other antivirals
- Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications
Influenza due to identified seasonal influenza virus
☐

Pegylated interferon alfa (2a) General information

Section
Medicines for hepatitis C > Other antivirals for hepatitis C
- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications
Chronic hepatitis C

☐

Pegylated interferon alfa (2b) General information

Section
Medicines for hepatitis C > Other antivirals for hepatitis C
- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications
Chronic hepatitis C
☐

Raltegravir General information

Section
Antiretrovirals > Integrase inhibitors
- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Ravidasvir General information

Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
- Oral > Solid > tablet: 200 mg

Indications
Chronic hepatitis C
☐

Ribavirin General information

Section
Medicines for hepatitis C > Other antivirals for hepatitis C
- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications
Chronic hepatitis C
Section
Other antivirals
- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications
Viral haemorrhagic fever, not elsewhere classified
☐

Ritonavir General information

Section
Antiretrovirals > Protease inhibitors
- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Saquinavir General information

Section
Antiretrovirals > Protease inhibitors
- Oral > Solid: 200 mg; 500 mg

Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
☐

Simeprevir General information

Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

Chronic hepatitis C

☐

Sofosbuvir General information

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

Chronic hepatitis C

☐

Sofosbuvir + velpatasvir General information

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

Chronic hepatitis C

☐

Stavudine General information

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

☐

Tenofovir alafenamide General information

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 25 mg

Indications

Chronic hepatitis B

☐

Tenofovir disoproxil fumarate General information

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Chronic hepatitis B

☐

Valganciclovir General information

Section

Other antivirals

- Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
- Oral > Solid > tablet: 450 mg (as hydrochloride)

Indications

Cytomegaloviral retinitis

☐

Zidovudine General information

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified